Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00KZF
|
||||
| Former ID |
DNC003753
|
||||
| Drug Name |
BMY-7378
|
||||
| Drug Type |
Small molecular drug
|
||||
| Formula |
C22H31N3O3
|
||||
| InChI |
InChI=1S/C22H31N3O3/c1-28-19-7-3-2-6-18(19)24-13-10-23(11-14-24)12-15-25-20(26)16-22(17-21(25)27)8-4-5-9-22/h2-3,6-7H,4-5,8-17H2,1H3
|
||||
| InChIKey |
AYYCFGDXLUPJAQ-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
5510237, 7978802, 8151616, 11110816, 11113851, 14878226, 26752024, 29221583, 47440473, 50070413, 50071054, 50104690, 53790375, 57321308, 74517605, 85208977, 85788125, 90341693, 103175652, 103808191, 103936501, 104300530, 117592230, 124749543, 124879359, 124879360, 124879361, 124879362, 127479091, 134340958, 135069971, 135650009, 136368030, 137006976, 137952632, 144115742, 162814196, 179150156, 198949361, 223621325, 231780292, 250078613
|
||||
| Target and Pathway | |||||
| Target(s) | Alpha-1D adrenergic receptor | Target Info | Inhibitor | [527512] | |
| Alpha-1A adrenergic receptor | Target Info | Inhibitor | [527512] | ||
| 5-hydroxytryptamine 1A receptor | Target Info | Inhibitor | [534142] | ||
| Alpha-1B adrenergic receptor | Target Info | Inhibitor | [527512] | ||
| KEGG Pathway | Calcium signaling pathway | ||||
| cGMP-PKG signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Adrenergic signaling in cardiomyocytes | |||||
| Vascular smooth muscle contraction | |||||
| Salivary secretionhsa04020:Calcium signaling pathway | |||||
| AMPK signaling pathway | |||||
| Salivary secretionhsa04024:cAMP signaling pathway | |||||
| Serotonergic synapsehsa04020:Calcium signaling pathway | |||||
| Salivary secretion | |||||
| NetPath Pathway | IL2 Signaling PathwayNetPath_14:IL2 Signaling Pathway | ||||
| Pathway Interaction Database | LPA receptor mediated events | ||||
| WikiPathways | Monoamine GPCRs | ||||
| Calcium Regulation in the Cardiac Cell | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| GPCRs, OtherWP58:Monoamine GPCRs | |||||
| Endothelin Pathways | |||||
| AMPK SignalingWP722:Serotonin HTR1 Group and FOS Pathway | |||||
| SIDS Susceptibility Pathways | |||||
| GPCR downstream signalingWP58:Monoamine GPCRs | |||||
| Vitamin D Receptor Pathway | |||||
| AMPK Signaling | |||||
| References | |||||
| Ref 543289 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 9). | ||||
| Ref 544847 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001317) | ||||
| Ref 527512 | J Med Chem. 2005 Apr 21;48(8):3076-9.Synthesis and structure-activity relationship of fluoro analogues of 8-{2-[4-(4-methoxyphenyl)piperazin-1yl]ethyl}-8-azaspiro[4.5]decane-7,9-dione as selective alpha(1d)-adrenergic receptor antagonists. | ||||
| Ref 534142 | J Med Chem. 1996 Mar 1;39(5):1125-9.8-[4-[2-(1,2,3,4-Tetrahydroisoquinolinyl]butyl-8-azaspiro[4.5]decane-7,9-dione: a new 5-HT1A receptor ligand with the same activity profile as buspirone. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.